Sign in

CIK 0001528287

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

NeuroPace Inc

Sign in to watch
Ticker
NPCE
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
223550230
Phone
+1 650-237-2700
Business address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW, CA, 94043
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2021-06-04 Ridley Irina General Counsel and Secretary Grant or award +5,681 8,033
2021-06-04 Ridley Irina General Counsel and Secretary Grant or award · Stock Option (Right to Buy) +11,363 11,363
2021-04-26 Fischer Frank M Director Conversion +472,366 565,657
2021-04-26 Fischer Frank M Director Conversion · Series A' Preferred Stock −21,486 0
2021-04-26 Fischer Frank M Director Conversion · Series B' Preferred Stock −450,880 0
2021-04-26 ORBIMED ADVISORS LLC 10% owner Conversion +3,777,281 4,012,281
2021-04-26 ORBIMED ADVISORS LLC 10% owner Conversion · Series A' Preferred Stock −171,895 0
2021-04-26 ORBIMED ADVISORS LLC 10% owner Conversion · Series B' Preferred Stock −3,605,386 0
2021-04-26 Norton Evan Director Conversion +3,454,422 4,042,657
2021-04-26 Norton Evan Director Conversion · Series B' Preferred Stock −3,454,422 0
2021-04-26 Accelmed Partners II L.P. 10% owner Conversion +3,454,422 4,042,657
2021-04-26 Accelmed Partners II L.P. 10% owner Conversion · Series B' Preferred Stock +3,454,422 3,454,422
2021-04-26 Garfield Greg Shaw Director Conversion +18,891 18,891
2021-04-26 Garfield Greg Shaw Director Conversion +5,595,493 5,614,384
2021-04-26 Garfield Greg Shaw Director Conversion · Series A' Preferred Stock −859 0
2021-04-26 Garfield Greg Shaw Director Conversion · Series B' Preferred Stock −18,032 0
2021-04-26 Garfield Greg Shaw Director Conversion · Series A' Preferred Stock −323,591 0
2021-04-26 Garfield Greg Shaw Director Conversion · Series B' Preferred Stock −5,271,902 0
2021-04-26 Favet Michael Chief Executive Officer Conversion +7,562 7,562
2021-04-26 Favet Michael Chief Executive Officer Grant or award +15,385 $0.03 $462 22,947

Page 17 of 19 · 362 trades